Related Experiment Video
Updated: Mar 30, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
13.0K
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective
Merrilee Needham1,2,3, Frank L Mastaglia4,5
1Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 6150, WA, Australia. Merrilee.Needham@health.wa.gov.au.
Summary
Current immune-mediated inflammatory myopathies treatments are often empirical. This review discusses novel therapies targeting B cells, T cells, and cytokines for patients with limited response to conventional treatments.
Area of Science:
- Immunology
- Neurology
- Rheumatology
Background:
- Immune-mediated inflammatory myopathies (IMIMs) traditionally treated with glucocorticoids, immunosuppressants, and IVIg.
- A significant portion of patients exhibit partial or transient responses to current therapies.
- Inclusion body myositis (IBM) patients are particularly resistant to conventional immunotherapies.
Purpose of the Study:
- To review current treatment approaches for IMIMs.
- To explore novel therapeutic strategies for IMIMs.
- To discuss emerging treatments targeting specific immune cells and cytokines.
Main Methods:
- Literature review of existing and emerging IMIM treatments.
- Analysis of novel therapeutic targets including B cells, T cells, and cytokines.
- Discussion of treatment approaches for different IMIM subtypes.
Main Results:
- Conventional therapies show limited efficacy in a subset of IMIM patients, especially IBM.
- Emerging targeted therapies show promise for improving treatment outcomes.
- Understanding IMIM subtypes and pathogenesis is crucial for personalized treatment.
Conclusions:
- Novel immunotherapies targeting specific cellular and cytokine pathways represent a promising advancement in IMIM treatment.
- Personalized treatment strategies based on IMIM subtypes and pathogenesis are essential.
- Further research and clinical trials are needed to validate these novel therapies.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
669
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
01:15Myasthenia Gravis: Diagnostic Tests
3.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.1K
01:14Myocarditis III: Medical Management
319
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
319
01:29Inflammatory Bowel Disease IV: Pharmacological Management
935
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
935